Pretzel Therapeutics Secures UK Approval to Advance PX578 Into Clinical Trials for POLG-Related Mitochondrial Disorders

Pretzel Therapeutics Receives UK MHRA Authorization for PX578 Phase 2 Trial in POLG-Mediated Mitochondrial Disease Pretzel Therapeutics, Inc., a clinical-stage biotechnology company developing a new class of medicines intended to…

Read MorePretzel Therapeutics Secures UK Approval to Advance PX578 Into Clinical Trials for POLG-Related Mitochondrial Disorders

Genmab Reports Significant Survival and Response Benefits with Petosemtamab Combination in First-Line Head and Neck Cancer

Genmab Reports Positive Phase 3 LiGeR-HN1 Results for Petosemtamab Plus Pembrolizumab in Head and Neck Cancer Genmab A/S, a biotechnology company focused on developing innovative antibody-based medicines for serious diseases,…

Read MoreGenmab Reports Significant Survival and Response Benefits with Petosemtamab Combination in First-Line Head and Neck Cancer